CL King Reiterates Buy Rating on Boston Scientific (BSX)

Go back to CL King Reiterates Buy Rating on Boston Scientific (BSX)

Boston Scientific Announces Results for Third Quarter 2024

October 23, 2024 6:30 AM EDT

MARLBOROUGH, Mass., Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to... More